OMass Therapeutics
- Health & Biotech
- Oxford, GB
- Founded 2016
- Private
- omass.com
University of Oxford spin-out discovering small-molecule medicines for endocrine and immunological diseases.
$310MEquity raised in 2025–20262025 — · 2026 $310M · 1 equity round
$410MEquity raised, all time4 equity rounds on record
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 4 rounds · 4 sources · newest first
- Series CAmount$310MGBP 230MPost-money—✓ Confirmed
- Series BAmount$100MGBP 75.5MPost-money—✓ Confirmed
- Extended Series AAmount—GBP 27.5MPost-money—✓ Confirmed
- Series AAmount—GBP 14MPost-money—✓ Confirmed
Investors 13
- Oxford Science Enterprises4
- Syncona4
- GV2
- Northpond Ventures2
- Sanofi2
- Bain Capital Life Sciences1
- Forbion1
- Novo Holdings1
- University of Oxford3
- British Business Bank
- Janus Henderson Investors
- Jefferson Life Sciences
- SV Health Investors
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
MapLight TherapeuticsHealth · $373M in 2025–2026Shared: Sanofi, Forbion +1AdvanCellHealth · $315M in 2025–2026Shared: Sanofi, Bain Capital Life Sciences +1Parabilis MedicinesHealth · $975M in 2025–2026Shared: GV, Janus Henderson InvestorsFractileAI Infra · $940M in 2025–2026Shared: Oxford Science Enterprises, British Business BankEncoded TherapeuticsHealth · $275M in 2025–2026Shared: GV, Janus Henderson InvestorsSambaNovaAI Infra · $1.4B in 2025–2026Shared: GV
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. OMass Therapeutics and its logo are trademarks of their owners, used here for identification only.
